Zhao Yinjiao, Song Peiyu, Zhang Hui, Chen Xiaoyu, Han Peipei, Yu Xing, Fang Chenghu, Xie Fandi, Guo Qi
Jiangwan Hospital of Shanghai Hongkou District, Shanghai University of Medicine and Health Science Affiliated First Rehabilitation Hospital, Shanghai, China.
Department of Rehabilitation Medicine, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Front Aging Neurosci. 2022 Jul 26;14:951146. doi: 10.3389/fnagi.2022.951146. eCollection 2022.
Unbiased metabolic profiling has been initiated to identify novel metabolites. However, it remains a challenge to define reliable biomarkers for rapid and accurate diagnosis of mild cognitive impairment (MCI). Our study aimed to evaluate the association of serum metabolites with MCI, attempting to find new biomarkers and combination models that are distinct for MCI.
A total of 380 participants were recruited (mean age: 72.5 ± 5.19 years). We performed an untargeted metabolomics analysis on older adults who underwent the Mini-Mental State Examination (MMSE), the Instrumental Activities of Daily Living (IADL), and physical performance tests such as hand grip, Timed Up and Go Test (TUGT), and walking speed. Orthogonal partial least squares discriminant analysis (OPLS-DA) and heat map were utilized to distinguish the metabolites that differ between groups.
Among all the subjects, 47 subjects were diagnosed with MCI, and methods based on the propensity score are used to match the MCI group with the normal control (NC) group ( = 47). The final analytic sample comprised 94 participants (mean age: 75.2 years). The data process from the metabolic profiles identified 1,008 metabolites. A cluster and pathway enrichment analysis showed that sphingolipid metabolism is involved in the development of MCI. Combination of metabolite panel and physical performance were significantly increased discriminating abilities on MCI than a single physical performance test [model 1: the area under the curve (AUC) = 0.863; model 2: AUC = 0.886; and model 3: AUC = 0.870, < 0.001].
In our study, untargeted metabolomics was used to detect the disturbance of metabolism that occurs in MCI. Physical performance tests combined with phosphatidylcholines (PCs) showed good utility in discriminating between NC and MCI, which is meaningful for the early diagnosis of MCI.
已启动无偏代谢谱分析以鉴定新型代谢物。然而,定义用于快速准确诊断轻度认知障碍(MCI)的可靠生物标志物仍然是一项挑战。我们的研究旨在评估血清代谢物与MCI的关联,试图找到对MCI具有独特性的新生物标志物和组合模型。
共招募了380名参与者(平均年龄:72.5±5.19岁)。我们对接受简易精神状态检查表(MMSE)、日常生活活动能力量表(IADL)以及诸如握力、定时起立行走测试(TUGT)和步行速度等身体机能测试的老年人进行了非靶向代谢组学分析。采用正交偏最小二乘判别分析(OPLS-DA)和热图来区分不同组之间存在差异的代谢物。
在所有受试者中,47名受试者被诊断为MCI,并使用基于倾向评分的方法将MCI组与正常对照组(NC)进行匹配(n = 47)。最终分析样本包括94名参与者(平均年龄:75.2岁)。代谢谱的数据处理鉴定出1008种代谢物。聚类和通路富集分析表明鞘脂代谢参与了MCI的发生发展。代谢物面板与身体机能的组合对MCI的鉴别能力显著高于单一身体机能测试[模型1:曲线下面积(AUC)= 0.863;模型2:AUC = 0.886;模型3:AUC = 0.870,P < 0.001]。
在我们的研究中,非靶向代谢组学用于检测MCI中发生的代谢紊乱。身体机能测试与磷脂酰胆碱(PCs)相结合在区分NC和MCI方面显示出良好的效用,这对MCI的早期诊断具有重要意义。